Purchase this article with an account.
Deisy Nallely Delgado Arellano, Felipe Prado Vásquez, Miguel Pedroza Seres, Rosalva Yasha Bobadilla, Hae Jin Kim; Clinical and epidemiological description of Serpinginous Choroiditis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6672.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The Serpiginous choroiditis (SC) is a rare posterior uveitis displaying a geographic pattern of choroiditis, extending from the juxtapapillary choroid and intermittently spreading centrifugally. The choroiditis involves the overlying retinal pigment epithelium, and the outer retina. This intraocular inflammation typically involves both eyes in otherwise healthy, middle-aged individuals with no familial or ethnic predilection. The objective of our investigation is description of clinical features of SC.
The present investigation is a retrospective analysis of records between 2001 and 2017 patients of uveitis with diagnosis of SC. The electronic files of these patients were statistically analyzed. Data were collected: age, sex, chief complaint, visual acuity and clinical features. We excluded patients without at less 6 ophthalmology revision, without typical clinical features and infectious cause.
There were 24 subjects with diagnosis with SC, 19 (79.1%) subjects had bilateral affection and 5 (20.8%) were unilateral. 8 (33.3%) were men and rest of them were female 16 (66.6%). The youngest patient was 7 years old, the oldest patient was 89 years old and the average of age were 56.6. The main symptoms were blurred vision 20 (83%), metamorphopsia 1 (4.16%), pain 2 (8.3%) and foreign body sensation 1 (4.16%). 6 (25%) patients were complicated with choroidal neovascularization. 4 (16%) had anterior chamber cellularity and 3 (12.5%) had vitreous cellularity.
In conclusion, differentiation of SC from the mimicking choroiditis is vital for proper management and assessment of prognosis. Although pathogenesis, etiology, and differential diagnosis of the SC and the mimicking conditions remain a challenge. The treatment is with systemic corticosteroids and or additional immunosuppressive agents can reduce intraocular inflammation and minimize the required dose of systemic corticosteroids.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only